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Objective To determine the effect of intravenous vatinoxan administration on bradycardia, 2 
hypertension and level of anaesthesia induced by medetomidine-tiletamine-zolazepam in red 3 
deer (Cervus elaphus). 4 
Study design and animals A total of 10 healthy red deer were enrolled in a randomized, 5 
controlled, experimental, crossover study.  6 
Methods Deer were administered a combination of 0.1 mg kg-1 medetomidine hydrochloride 7 
and 2.5 mg kg-1 tiletamine-zolazepam intramuscularly, followed by 0.1 mg kg-1 vatinoxan 8 
hydrochloride or equivalent volume of saline intravenously (IV) 35 minutes after anaesthetic 9 
induction. Heart rate (HR), mean arterial blood pressure (MAP), respiration rate (fR), end-tidal 10 
CO2 (PE′CO2), arterial oxygen saturation (SpO2), rectal temperature (RT) and level of 11 
anaesthesia were assessed before saline/vatinoxan admi istration (baseline) and at intervals 12 
for 25 minutes thereafter. Differences within treatments (change from baseline) and between 13 
treatments were analysed with linear mixed effect models (p < 0.05).  14 
Results Maximal (81 ± 10 beats minute-1) HR occurred 90 seconds after vatinoxan injection 15 
and remained significantly above baseline (42 ± 4 beats minute-1) for 15 minutes. MAP 16 
significantly decreased from baseline (122 ± 10 mmHg) to a minimum MAP of 83 ± 6 mmHg 17 
60 seconds after vatinoxan and remained below baseline until end of anaesthesia. HR 18 
remained unchanged from baseline (43 ± 5 beats minute-1) with the saline treatment, while 19 
MAP decreased significantly (112 ± 16 mmHg) from baseline after 20 minutes. PE′CO2, fR, 20 
and SpO2 showed no significant differences between treatmens, while RT decreased 21 
significantly 25 minutes after vatinoxan. Level of anaesthesia was not significantly influenced 22 
by vatinoxan. 23 
Conclusion and clinical relevance Vatinoxan reversed hypertension and bradycardia 24 
induced by medetomidine without causing hypotension or affecting the level of anaesthesia in 25 
red deer. However, the effect on HR subsided 15 minutes after vatinoxan IV administration. 26 
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Vatinoxan has the potential to reduce anaesthetic side effects in non-domestic ruminants 27 
immobilized with medetomidine-tiletamine-zolazepam.  28 
Keywords bradycardia, hypertension, medetomidine, red deer, vatinoxan 29 
  30 
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Introduction (Word count 3668) 31 
Chemical immobilization and anaesthesia are often essential for handling and medical 32 
interventions of captive and free-ranging non-domestic pecies. Induction of balanced 33 
anaesthesia in non-domestic species by injectable ana sthetics often requires high doses of 34 
drug combinations such as dissociative anaesthetics combined with α2-adrenoceptor agonists 35 
(Grimm & Lamont 2007). In non-domestic ruminants, α2-adrenoceptor agonists, such as 36 
medetomidine, are the most frequently represented drug class (Masters 2015), and are 37 
commonly combined with ketamine (Arnemo et al. 2005) or tiletamine-zolazepam (Barasona 38 
et al. 2013).  39 
While the sedative and analgesic effects of α2-adrenoceptor agonists are mediated by 40 
central α2-adrenoceptors located in the central nervous system, he activation of peripheral 41 
α2-adrenoceptors causes peripheral vasoconstriction and a consequent increase in arterial 42 
blood pressure (Langer et al. 1980). In non-domestic ruminants, this can result in severe 43 
hypertension (Sainmaa et al. 2019). Furthermore, baroreceptor mediated sinus bradycardia 44 
together with a decreased cardiac output regularly occur in animals sedated with 45 
medetomidine (Bryant et al. 1996; Murrell & Hellebrkers 2005). The dose-dependent 46 
cardiovascular side effects should be considered, since the doses of α2-adrenoceptor agonists 47 
used in non-domestic ruminant anaesthesia (Williams et al. 2018) often exceed those required 48 
for their domestic relatives, e.g. sheep (Bryant et al. 1996) by 3 - 4 times. 49 
The peripheral α2-adrenoceptor antagonist vatinoxan (MK-467) alleviates the 50 
peripheral cardiovascular and pulmonary effects of α2-adrenoceptor agonists while 51 
maintaining sedation, as shown in many domestic speies, such as dogs (Honkavaara et al. 52 
2008; Honkavaara et al. 2011), cats (Honkavaara et al. 2017b; Pypendop et al. 2017), horses 53 
(Bryant et al. 1998; de Vries et al. 2016) and sheep (Bryant et al. 1998; Raekallio et al. 2010; 54 
Adam et al. 2018a). In contrast to the widely used antagonist for α2-adrenoceptor agonists 55 
atipamezole, it mainly affects peripheral receptors due to its minimal ability to cross the 56 
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blood-brain barrier (Clineschmidt et al. 1988). Therefore, vatinoxan does not substantially 57 
affect the sedation mediated by α2-adrenoceptors located in the central nervous system 58 
(Honkavaara et al. 2008). Moreover, vatinoxan can be safely used with atipamezole as 59 
demonstrated in medetomidine sedated sheep (Adam et l. 2018a). 60 
The aim of this study was to evaluate the effect of vatinoxan on heart rate (HR) and 61 
blood pressure after intravenous (IV) bolus administration in red deer (Cervus elaphus) 62 
anaesthetized with medetomidine-tiletamine-zolazepam. We hypothesized that vatinoxan 63 
would alleviate the bradycardia and hypertension induced by medetomidine in red deer 64 
without markedly affecting the level of anaesthesia. 65 
Material and methods 66 
A total of 10 healthy 7-month-old red deer (male = 4; female = 6) with a mean body weight of 67 
69.6 kg (standard deviation: ± 10.3 kg; range: 53 - 89 kg) were included in the study. The 68 
animals originated from the red deer population kept in a 45 hectare enclosure adjacent to the 69 
Research Institute of Wildlife Ecology (48.21°N, 16.37°E), under conditions that approximate 70 
those in the wild. All procedures and experiments were approved by the institutional ethics 71 
and animal welfare committee and the Animal experimntal committee of the Federal 72 
Ministry of Science, Research and Economy in accordance to the Austrian Animal 73 
Experimentation Act (Tierversuchsgesetz 2012) (BMWFW-68.205/0191-WF/V/3B/2017), the 74 
guidelines for good scientific practice and national legislation.  75 
The study was carried out as a randomized, controlled, experimental, crossover study, 76 
with a wash-out period between treatments of 14 - 16 days. Each animal was studied on two 77 
occasions and randomly allocated to two treatments by flipping a coin in the first trial round. 78 
Animals were given the opposite treatment in the second trial round. Allocation into the 79 
specific treatment was carried out by the same anaesthetist (JP), who was responsible for drug 80 
calculations and preparations and was not involved in ata acquisition. The blinded data 81 
acquisition was done by another investigator (JE) throughout the project. The exclusion 82 
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criterion was incomplete administration of the initial medetomidine-tiletamine-zolazepam 83 
dose, which occurred in one animal.  84 
Anaesthesia was induced with 0.1 mg kg-1 medetomidine (20 mg mL-1, Medetomidine-85 
hydrochloride 2%, magistral formula by Richter Pharm  AG, Austria) combined with 2.5 mg 86 
kg-1 tiletamine-zolazepam (Zoletil, Virbac Österreich GmbH, Austria) administered 87 
intramuscularly (IM) followed by 1) 0.1 mg kg-1 vatinoxan (VAT) (Vetcare Finland Oy, 88 
Finland) (referred to as VAT) or 2) equivalent volume of saline 0.9 % in mL (Isotonic sodium 89 
chloride solution 0.9 % ad us. vet., B. Braun GmbH, Austria) (referred to as Control). 90 
Vatinoxan HCl, in powder form, was dissolved in sterile 0.9 % saline solution to a final 91 
concentration of 2.5 mg mL-1. Both treatments were administered IV 35 minutes after 92 
medetomidine-tiletamine-zolazepam.  93 
Animals were led into a walled corral located in their enclosure by a professional 94 
animal trainer. This procedure was practiced before by positive reinforcement training in 95 
order to familiarise the animals with the procedure and provide stress-free handling and 96 
anaesthetic induction. The animals were then remotely injected using a filled dart (3 mL dart 97 
syringe, Dan-Inject, Denmark) projected into the caudo-lateral aspect of the pelvic limb 98 
(Musculus biceps femoris) via blowpipe (BLOW 1.25 Model Zoo, Dan-Inject, Denmark) with 99 
medetomidine-tiletamine-zolazepam mixed in the same syringe. When the dart had fully 100 
discharged this was recorded as the start of anaesthesia and measured using a stopwatch. 101 
Subsequent sampling timepoints were taken from timehe stopwatch was started. To avoid 102 
any visual or auditory stimulation by the research team, the animal was observed by one 103 
person who monitored it through a small opening in the corral wall. As soon as the recumbent 104 
deer became unresponsive to auditory stimuli, the corral was entered by one veterinarian to 105 
confirm an adequate level of anaesthesia (i.e. no response to physical stimulation, assessment 106 
of pupil dilation and loss of palpebral reflex). Deer were then blindfolded, placed in right 107 
lateral recumbency and transported to the clinic within 10 minutes. The animals were 108 
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intubated (HS Endotracheal Tube, Inner Diameter 8.0 mm, Length 32 cm Murphy, Henry 109 
Schein Animal Health, Czech Republic) and were given 100 % oxygen (2 L minute-1) until 110 
the end of anaesthesia. An arterial catheter (Insyste-A Arterienkatheter 22 Gauge, Length 38 111 
mm, Becton Dickinson, Germany) was placed in the Arteria auricularis caudalis and a 112 
venous catheter (Vasofix Safety 18 Gauge, Length 45 mm, B. Braun Austria GesmbH, 113 
Austria) in the Vena jugularis. The transducer of the arterial catheter was calibrated before 114 
each experiment against a mercury column and zeroed to atmospheric pressure at the level of 115 
the sternum with the red deer in lateral recumbency.  116 
Baseline values were recorded 30 minutes after the injection of medetomidine-117 
tiletamine-zolazepam and included HR, respiratory rate (fR), end-tidal CO2 (PE′CO2), 118 
electrocardiogram (ECG), haemoglobin oxygen saturation using pulse oximetry (SpO2), rectal 119 
temperature (RT), and direct mean (MAP), systolic (SAP) and diastolic (DAP) arterial blood 120 
pressures. The variables PE′CO2, fR, SpO2 (Root
 with Noninvasive Blood Pressure and 121 
Temperature Monitoring; Radical-7; Phasein ISA; Masimo Corporation, CA, USA) and 122 
continuous lead II ECG, HR, MAP, SAP, DAP (PM-8000 Express, Mindray Medical 123 
Germany GmbH, Germany) were measured using multiparameter monitors. Rectal 124 
temperature was determined using a digital thermometer (HS Digital Veterinary 125 
Thermometer, Henry Schein Animal Health, Czech Republic).  126 
Anaesthetic level was assessed by using the following scoring system: Degree of 127 
hypnosis was assessed by the palpebral and perineal eflexes tested by tactile stimulation (up 128 
to 3 times within 10 seconds) of the naso-ventral canthus of the eye and the perianal skin. 129 
Reflex response was scored with 0 = absent; 1 = slight (reflex/response could be induced only 130 
by repeated stimulus); 2 = slight but definitely present response; 3 = brisk, normal response. 131 
Evaluation of antinociception was assessed by the pedal reflex in response to pinching (up to 132 
3 times within 10 seconds) the interdigital space using the same scoring system as described 133 
earlier.  134 
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Treatment with VAT or an equal volume of saline followed 35 minutes after 135 
induction, and was injected over a 30 second period (T = -0.5 to T = 0), at 5 minutes after 136 
baseline.  137 
Immediately after the end of treatment application (T = 0) (VAT or Control), SAP, DAP, 138 
MAP, ECG and HR were documented at 10 second-intervals for 2 minutes, 60 second-139 
intervals for the following 8 minutes until T = 10 and 5 minute-intervals for the remaining 15 140 
minutes (T = 15-T = 25). 141 
The variables PE′CO2, fR, RT, SpO2 and depth of anaesthesia were documented 5 142 
minutes before (baseline T = -5) and 5 (T = 5), 10 (T = 10), 15 (T = 15), 20 (T = 20) and 25 143 
minutes (T = 25) after VAT or saline treatment, resulting in a total anaesthesia duration of 60 144 
minutes. The animals were returned to their enclosure, extubated and injected with 145 
atipamezole (Antisedan, Vetoquinol GmbH, Germany) dosed at 5 μg for each 1 μg of 146 
medetomidine IM into the lateral muscles of the shoulder girdle (Musculus deltoideus). All 147 
animals were observed until complete recovery. 148 
Statistical analysis 149 
Statistical analyses were performed by use of RStudio (R version 3.4.1; R Core Team 2017).  150 
Power analysis based on data previously obtained in our laboratory suggested that 10 deer 151 
would permit the detection of a 24% difference in MAP with a standard deviation (SD) of 19 152 
mmHg between VAT and control treatment, with an alph  level of 0.05 and a power of 0.95. 153 
The Shapiro-Wilk normality test was used to assess data distributions. The normal 154 
distribution of model residuals was visually determined with qq-plots and histograms. To 155 
adjust for repeated measurements and to avoid pseudo-r plication, differences between 156 
treatments were evaluated with a repeated measures analysis of linear mixed effects models 157 
(nlme package, Pinheiro et al. 2017) with multiple comparisons (VAT versus Control). 158 
Changes in physiological variables were analysed with a post-hoc test (Tukey Honestly 159 
Significant Difference) over-time within treatments (change from baseline) and between 160 
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treatments, as well as at selected time points for time x treatment interaction effects (lsmeans 161 
package, Lenth 2016). Regarding level of anaesthesia, data were not normally distributed, 162 
therefore a nonparametric test (Kruskal-Wallis test) was used to assess differences between 163 
treatments. Data are reported as mean ± SD. Statistic l ignificance was set at p < 0.05. 164 
Results 165 
The VAT administration resulted in a significant decrease in arterial blood pressure and a 166 
significant increase in HR. The MAP (Fig. 1), DAP (Fig. 2) and SAP (Fig. 3) significantly 167 
decreased by a mean of 34 % from baseline after VATand remained below baseline values 168 
until end of anaesthesia. Minimum values were obtained 110 seconds after VAT injection. 169 
Blood pressures differed significantly between Contr l and VAT at all time points 170 
(Figs. 1-3, Table 1). In the Control treatment, MAP, SAP and DAP decreased significantly 171 
below baseline 20 minutes after saline injection (Figs. 1-3).  172 
For HR, a significant difference between Control and VAT treatment was detected 10 173 
seconds after injection lasting for 15 minutes (Fig. 4, Table 1). The HR significantly increased 174 
10 seconds after injection of VAT by an average of 102% 3 minutes after injection and 175 
remained significantly above baseline for 15 minutes (Fig. 4). In the Control treatment no 176 
significant difference for HR from baseline was detected (Fig. 4).  177 
The SpO2 was significantly increased in both treatments at all time points after 178 
treatment compared with baseline (Table 1). No significant difference between treatments was 179 
observed for SpO2. 180 
The RT (Table 1) was significantly lower with VAT treatment than with Control 181 
treatment. RT started to decrease significantly below baseline 5 minutes after VAT treatment 182 
and 25 minutes after Control treatment. 183 
No significant difference within and between VAT and Control treatment occurred for 184 
PE′CO2 and fR during the observation period (Table 1).  185 
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Except for respiratory sinus arrhythmia with both trea ments (VAT: 8 animals; 186 
Control: 7 animals), no ECG abnormality was detected.  187 
Level of anaesthesia showed neither a difference between treatments nor a time-188 
treatment interaction or influence of time. No perin al- or pedal reflexes were detected, but all 189 
animals showed moderate palpebral eye reflexes (range: 0-2; mean: 1.4 ± 0.5) throughout the 190 
observation period.  191 
Discussion 192 
The combination of medetomidine-tiletamine-zolazepam induced both bradycardia and 193 
hypertension in all deer in the present study. IV administration of VAT alleviated these 194 
changes without causing hypotension or affecting the degree of anaesthesia. However, while 195 
the reduction of blood pressure lasted until the end of the anaesthesia, the effect on HR 196 
subsided 15 minutes after VAT. Respiratory variables fR, PE′CO2, and SpO2 were within 197 
physiological ranges and showed no significant difference between the treatments in 198 
anaesthetized deer supplemented with oxygen. 199 
Physiological reference values for blood pressure and HR in conscious deer are 200 
unavailable, as the majority of data collection in wildlife species takes place in anaesthetized 201 
animals. In the present study, resting HR for deer (mean: 84 ± 3 beats minute-1) and cut-off 202 
points for bradycardia and tachycardia were calculated according to the formula 241* 203 
bodyweight-0.25 (Heard 2007), as in a study by Sainmaa et al. (2019) in markhors. A HR more 204 
than 20% below or above this value was interpreted as brady- or tachycardia (Heard 2007). 205 
Thus, baseline HR of all animals in the present study may be considered bradycardic. 206 
Baseline MAP values after medetomidine-tiletamine-zola epam administration were 207 
increased compared to normotensive values in other mammalian species (e.g. goats and 208 
sheep: MAP 75–100 mmHg; Riebold 2015) and therefore considered hypertensive. Both 209 
hypertension and bradycardia are well-known side eff cts of medetomidine (Bryant et al. 210 
1996; Murrell & Hellebrekers 2005). Nevertheless, tiletamine-zolazepam used in the present 211 
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study could have additionally impacted blood pressure and HR (Lin et al. 1989; Lin et al. 212 
1993). However, tiletamine causes an increase in HR or even tachycardia due to an increased 213 
sympathetic tone in species such as dogs (Cullen & Reynoldson 1997) and cats (Yanmaz et al. 214 
2017). Therefore, the bradycardic effect in this study can probably be mostly attributed to 215 
medetomidine. Furthermore, a study in horses showed an increase in HR after tiletamine-216 
zolazepam application reversing detomidine induced bra ycardia (Wan et al. 1992).  217 
However, tiletamine-zolazepam could impact blood pressure, due to increased 218 
sympathetic systemic vascular resistance (Lin et al. 1993). In calves (Lin et al. 1989) 219 
administered tiletamine-zolazepam, arterial blood pressure was characterized by biphasic 220 
decreases followed by an increase. In other ruminants such as sheep no significant changes in 221 
blood pressure and HR were detected even with up to five times higher doses (15 mg kg-1 222 
tiletamine-zolazepam) than that used in the present tudy (Taylor et al. 1992). Nevertheless, 223 
an enhancing effect by tiletamine-zolazepam on hypertension in the present study due to the 224 
sympathomimetic effects of the dissociative drug tiletamine cannot be discounted. While 225 
VAT reversed hypertension and bradycardia in this study, no hypotension occurred. 226 
No effect of VAT administration was detected on the level of anaesthesia. However, a 227 
shortened duration of the sedative effect of medetomidine may have been undetectable in our 228 
study as the anaesthetic effect of tiletamine-zolazep m was present during the observation 229 
period. The shorter duration of sedation has previously described in dogs administered 230 
dexmedetomidine (Honkavaara et al. 2012). Furthermore, assessment of anaesthetic level by 231 
reflex testing as performed in the present study might be limited and could be further refined 232 
in future studies. 233 
While blood pressure remained significantly below baseline until the end of 234 
anaesthesia, HR returned to baseline values 15 minutes after VAT. This is in contrast to other 235 
studies in dogs, where the influence of VAT on HR was sustained for longer time periods of 236 
60 - 90 minutes (Honkavaara et al. 2011; Restitutti et al. 2017). The comparatively short 237 
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effect of VAT on HR in this study might be attributed to differences in the pharmacokinetics 238 
between IM medetomidine and IV VAT, resulting in diverging changes in their plasma 239 
concentrations over time. For example in dogs, the concentration of VAT in plasma decreased 240 
rapidly during the first 10 minutes after an IV injection (Honkavaara et al. 2012) whereas the 241 
concentration of medetomidine changed relatively little between 30 and 90 minutes after IM 242 
administration (Restitutti et al. 2017). This corresponds to the time frame when VAT was 243 
administered to the red deer. Therefore, in our study, the concentration of VAT might have 244 
been only high enough to compete with medetomidine a d to replace it at the receptor sites 245 
briefly. However, differences in duration of cardiovascular effects might also be attributed to 246 
species differences in the half-lives of VAT (IV). Plasma half-life of VAT in dogs is 247 
approximately 40 - 60 minutes (Honkavaara et al. 2012), whereas in horses plasma half-lives 248 
of 140 - 170 minutes have been reported (de Vries et al. 2016). Therefore, studies of plasma 249 
drug concentration profiles would be desirable in order to understand bioavailability and 250 
pharmacokinetics according to administration route and species. Furthermore, species-specific 251 
sensitivity towards VAT and α2-adrenoceptor agonists might also explain differences in 252 
effects on HR. Studies in dogs (Honkavaara et al. 2008), and in sheep (Raekallio et al. 2010) 253 
with the same dose ratios of dexmedetomidine (0.005 mg kg-1) and VAT (0.25 mg kg-1) 254 
indicate a species-specific effect of VAT on  HR. Duration of changes in HR after 255 
dexmedetomidine/VAT administration lasted longer in dogs (40 minutes) than in sheep (20 256 
minutes). Moreover, Bryant et al. (1998) showed a greater attenuation of medetomidine-257 
induced hypertension in sheep given VAT than that observed in horses. A greater sensitivity 258 
to the vasodilatory effects of VAT in the presence of dexmedetomidine has furthermore been 259 
proposed for cats when compared with dogs (Honkavaar  et al. 2011). Additional studies in 260 
wildlife species such as red deer are required to investigate the different mechanisms 261 
underlying this variation in species-specific sensitivity. However, the return of HR to baseline 262 
values independently from the sustained normotension in this study may be attributed to a 263 
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combination of low sympathetic tone due to medetomidine-induced central sympatholysis in 264 
combination with a diminishing baroreceptor reflex. Hypertension induced by α2-265 
adrenoceptor agonists is known to subside over time (Savola 1989). Therefore, blood pressure 266 
probably remained low due to central effects of medetomidine (e.g. sedation, central 267 
sympatholysis and the resulting bradycardia), despit  the potentially vanishing effect of VAT 268 
in this study. This proposed mechanism is supported by the significant decrease of MAP 269 
below baseline after 20 minutes in the control treatment. Even though challenging in wildlife 270 
species it would be desirable to assess cardiovascular variables shortly after induction of 271 
anaesthesia in order to better understand the cardiovascular dynamics as well as the effect of 272 
an earlier or concomitant VAT application. In contrast to the majority of studies that 273 
administered VAT concomitantly with an α2-adrenoceptor agonist in the induction phase 274 
(Honkavaara et al. 2017b; Pypendop et al. 2017), animals in this study were given VAT  35 275 
minutes after medetomidine-tiletamine-zolazepam application.  276 
Cardiovascular effects of VAT are furthermore dose dependent in several species, 277 
such as dogs (Honkavaara et al. 2011; Restitutti et al. 2017), and cats (Honkavaara et al. 278 
2017a; Honkavaara et al. 2017b). The comparable low d se of VAT (0.1 mg kg-1 IV) used in 279 
our study in contrast to previous studies administering VAT IV in cats for example 280 
(Honkavaara et al. 2017a; Pypendop et al. 2017), dogs (Honkavaara et al. 2008) and sheep 281 
(Raekallio et al. 2010) might have also influenced the duration of the effect on HR. However, 282 
Tapio et al. (2018) showed in horses, using a comparable dose of VAT (0.15 mg kg-1 IV) 10 283 
minutes after detomidine (0.02 mg kg-1 IV), a significant increase in HR that remained 284 
elevated for 90 minutes. Sainmaa et al. (2019), who administered various doses of VAT 285 
(0.117-0.297 mg kg-1) to markhors, did not detect a dose-dependent effect on HR, although 286 
the decrease in MAP correlated significantly with the dose of VAT. Thus, it needs to be 287 
verified, whether, and if so, higher doses influence the efficiency of VAT in red deer.  288 
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A decrease in RT over time was observed in the present tudy although no 289 
hypothermia (RT < 37°C) was detected. Hypothermia can occur in sedated and anaesthetized 290 
animals due to impaired thermoregulation and decreased metabolic activity (MacDonald et al. 291 
1988; Grimm & Lamont 2007). In the present study, RT decreased significantly from baseline 292 
with both treatments. However, with VAT treatment a decrease occurred sooner. In dogs 293 
treated with medetomidine/butorphanol, thermographic imaging of superficial temperature 294 
suggested that VAT may increase peripheral heat loss (Vainionpää et al. 2013), possibly 295 
counteracting increased peripheral vasoconstriction by α2-adrenoceptor agonists (Honkavaara 296 
et al. 2011). Therefore, regular monitoring of core temperature is emphasized when VAT is 297 
combined with α2-adrenoceptor agonists.  298 
PE′CO2, fR and SpO2 were within physiological limits and showed no significant 299 
differences between treatments in this study. However, all animals were given supplemental 300 
oxygen during the experiment. Therefore, a potential effect of VAT on ventilatory variables 301 
could not be assessed. Low prebaseline SpO2 levels may be attributed to the lack of direct 302 
oxygen supply as the animals were not given supplemental oxygen during transport. Once the 303 
animals were intubated and connected to oxygen, SpO2 values increased to clinically desirable 304 
levels. PE′CO2 was slightly elevated in all animals, which is commonly reported in deer 305 
anaesthetized with α2-adrenoceptor agonists (Boesch et al. 2011). Elevated PE′CO2 in the 306 
present study may have occurred due to central respiratory depression (e.g. from the 307 
anaesthetic drugs) or to increased production of CO2 (e.g. from exertion) or both causes. 308 
Impairment of gas exchange could have been further compromised by α2-adrenoceptor 309 
agonist induced pulmonary oedema, which is commonly described in ruminants (Kästner et 310 
al. 2007). Blood gas analysis and further investigation of oxygen delivery and utilization, that 311 
were not performed in the present study, are desirable in order to understand underlying 312 
pathophysiological effects that might impact pulmonary variables and oxygenation.  313 
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The recovery from anaesthesia after atipamezole administration was smooth and rapid 314 
without differences between treatments, as reported in previous studies in dogs and sheep 315 
(Honkavaara et al. 2008; Adam et al. 2018b). No prolonged recoveries due to tiletamine-316 
zolazepam or renarcotization was observed. 317 
Limitations of this study include the delayed assesment of cardiovascular variables 318 
and application of VAT due to working with a wildlife species. Restrictions and potential 319 
subjective bias limit the assessment of anaesthetic l vel. In addition, the lack of further 320 
assessment of effects on the cardiopulmonary system, e.g. arterial blood gases analysis 321 
restrains the information on the influence of VAT on xygenation. 322 
Conclusion 323 
The IV administration of vatinoxan alleviated cardiovascular side effects, such as 324 
hypertension and bradycardia, in immobilized non-domestic ruminants with medetomidine-325 
tiletamine-zolazepam. There was no significant effect of vatinoxan on the degree of 326 
anaesthesia and reversal of sedation by atipamezole. Vatinoxan has the potential to reduce 327 
anaesthetic side effects in immobilized non-domestic mammals.  328 
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Figure 1 Mean ± standard deviation of direct mean arterial blood pressure (mmHg) in 10 red 
deer administered intravenous either: 0.1 mg kg-1 vatinoxan or an equivalent volume of saline. 
The animals were anaesthetized with medetomidine (0.1 mg kg-1) and tiletamine/zolazepam 
(2.5 mg kg-1 IM) 35 minutes before vatinoxan or saline injection. Spaces between the graphs 
and timelines (x-axis) represent a change in time int rvals. *VAT group (dotted line) 
significantly different (all p < 0.05) from baseline (-5 minutes) at the respectiv time points. 
†Significantly different (all p < 0.05) from Control at the respective time points. Arrows 
represent: B = baseline (5 minutes before injection of vatinoxan or saline), SI = start injection 
of vatinoxan/saline, EI = end injection of vatinoxan or saline. 
 
Figure 2 Mean ± standard deviation direct systolic arterial blood pressure (mmHg) in 10 red 
deer receiving IV either: 0.1 mg kg-1 vatinoxan or an equivalent amount of saline. (See Fig. 1 
legend for medetomidine-tiletamine-zolazepam doses). Spaces between the graphs and 
timelines (x-axis) represent a change in time intervals. *VAT group (dotted line) significantly 
different (all p < 0.05) from baseline (-5 minutes) at the respectiv time points. †Significantly 
different (all p < 0.05) from Control at the respective time points. Arrows represent: B = 
baseline (5 minutes before injection of vatinoxan or saline), SI = start injection of vatinoxan 
or saline, EI = end injection of vatinoxan or saline. 
 
Figure 3 Mean ± standard deviation direct diastolic arterial blood pressure (mmHg) in 10 red 
deer receiving IV either: 0.1 mg kg-1 vatinoxan or an equivalent amount of saline. (see Fig. 1 
legend for medetomidine-tiletamine-zolazepam doses). Spaces between the graphs and 
timelines (x-axis) represent a change in time intervals. *VAT group (dotted line) significantly 
different (all p < 0.05) from baseline (-5 minutes) at the respectiv time points. †Significantly 
different (all p < 0.05) from Control at the respective time points. Arrows represent: B = 
baseline (5 minutes before injection of vatinoxan or saline), SI = start injection of vatinoxan 
or saline, EI = end injection of vatinoxan or saline. 
 
Figure 4 Mean ± standard deviation heart rate (beats minute-1) in 10 red deer given 
intravenously  either: 0.1 mg kg-1 vatinoxan or an equivalent amount of saline. (see Fig. 1 
legend  for medetomidine-tiletamine-zolazepam doses). Spaces between the graphs and 
timelines (x-axis) represent a change in time intervals. *VAT group (dotted line) significantly 
different (all p < 0.05) from baseline (-5 minutes) at the respectiv time points. †Significantly 
different (all p < 0.05) from Control at the respective time points. Arrows represent: B = 
baseline (5 minutes before injection of vatinoxan or saline), SI = start injection of vatinoxan 
or saline, EI = end injection of vatinoxan or saline. 
 
Table 1 Changes in physiological variables in red deer before and after intravenous administration of 0.1 mg kg-1 vatinoxan (VAT; n = 10) or saline (equal 
amount of mL of vatinoxan; Control; n = 10). End of injected treatment was at time 0. Data are presented as means ± standard deviation. All animals were 
administered supplemental oxygen. 
Variable Treatment  Time (minutes) 
-5 (baseline) 0 1 2 3 4 5 10 15 20 25 
HR (beats minute-1) Control    43 ± 5    42 ± 6   43 ± 5   45 ± 5   47 ± 9*   43 ± 5    44 ± 6    46 ± 8*    45 ± 7    45 ± 7    46 ± 7 
VAT    42 ± 4    44 ± 6   80 ± 9*†   81 ± 12*†   79 ± 14*†   73 ± 15*†    67 ± 17*†    57 ± 21*†    51 ± 17*    42 ± 3    44 ± 5 
SAP (mmHg) Control  145 ± 15  145 ± 15 144 ± 17 145 ± 16 145 ± 17 146 ± 17  145 ± 18  145 ± 18   144 ± 18  142 ± 17*  142 ± 17* 
VAT  151 ± 8  145 ± 8* 116 ± 8*† 119 ± 9*† 122 ± 10*† 126 ± 11*†  128 ± 10*†  131 ± 9*†  133 ± 8*†  13 ± 9*†  131 ± 9*† 
MAP (mmHg) Control  116 ± 15  117 ± 13 116 ± 15 117 ± 15 117 ± 12 116 ± 15  115 ± 16  114 ± 19  115 ± 15  112 ± 16*  110 ± 18* 
VAT  122 ± 10  116 ± 10*   83 ± 6*†   85 ± 6*†   88 ± 7*†   91 ± 6*†    94 ± 6*†    98 ± 9*†  102 ± 11*†    99 ± 10*†    99 ± 10*† 
DAP (mmHg) Control  103 ± 15  103 ± 12 101 ± 14 103 ± 15 104 ± 10 102 ± 13  100 ± 16    99 ± 19  100 ± 15    96 ± 15*    94 ± 19* 
VAT  109 ± 15  103 ± 16   68 ± 11*†   69 ± 11*†   72 ± 12*†   75 ± 12*†    79 ± 11*†    83 ± 15*†    87 ± 16*†    85 ± 14*†    84 ± 15* 
fR (breaths minute-1) Control    24 ± 8    24 ± 6 NA NA NA NA    24 ± 7    28 ± 11    29 ± 11    30 ± 11*    29 ± 10 
VAT    21 ± 9    24 ± 14 NA NA NA NA    23 ± 7    23 ± 9    21 ± 6†    24 ± 11    28 ± 9 
PE′CO2 (mmHg) Control    55 ± 9    57 ± 8 NA NA NA NA    59 ± 5    55 ± 6    57 ± 5    57 ± 6    58 ± 8 
 VAT    56 ± 7    59 ± 8 NA NA NA NA    60 ± 4    58 ± 6    59 ± 3    56 ± 8    54 ± 7 
PE′CO2 (kPa) Control    7.3 ± 1.2    7.6 ± 1.0 NA NA NA NA    7.9 ± 0.7    7.3 ± 0.9    7.7 ± 0.7    7.6 ± 0.8    7.7 ± 1.0 
VAT    7.5 ± 1.0    7.9 ± 1.1 NA NA NA NA    8.0 ± 0.5    7.3 ± 0.9    7.9 ± 0.4    7.3 ± 1.2    7.2 ± 0.9 
SpO2 (%) Control    90 ± 13    96 ± 4* NA NA NA NA    97 ± 2*    97 ± 2*    97 ± 2*    97 ± 2*    97 ± 1* 
VAT    93 ± 8    95 ± 3 NA NA NA NA    96 ± 2*    97 ± 2*    97 ± 2*    97 ± 2*    97 ± 2* 
RT (°C) Control 39.3 ± 0.7 39.3 ± 0.8 NA NA NA NA 39.2 ± 0.8 39.0 ± 0.7 38.9 ± 0.9* 39.0 ± 1.0* 39.0 ± 0.9 
VAT 38.9 ± 0.5 38.8 ± 0.5 NA NA NA NA 38.7 ± 0.6* 38.6 ± 0.5* 38.6 ± 0.6* 38.5 ± 0.7* 38.4 ± 0.7*† 
 
IV: intravenous; NA: not available; HR: heart rate; SAP: systolic arterial pressure (invasive); MAP: mean arterial pressure (invasive); DAP: diastolic arterial 
pressure (invasive); fR: respiratory rate; PE′CO2: end-tidal CO2; SpO2: oxygen saturation of arterial blood measured by pulse oximetry; RT: rectal temperature. 
*Significantly different from baseline (-5 minutes) (p < 0.05). †Significantly different from Control at this time point (p < 0.05). 




